WO1995003315A2 - Saccharides, their synthesis and use - Google Patents

Saccharides, their synthesis and use Download PDF

Info

Publication number
WO1995003315A2
WO1995003315A2 PCT/GB1994/001575 GB9401575W WO9503315A2 WO 1995003315 A2 WO1995003315 A2 WO 1995003315A2 GB 9401575 W GB9401575 W GB 9401575W WO 9503315 A2 WO9503315 A2 WO 9503315A2
Authority
WO
WIPO (PCT)
Prior art keywords
sugar
library
conjugate
saccharide
compound
Prior art date
Application number
PCT/GB1994/001575
Other languages
French (fr)
Other versions
WO1995003315A3 (en
Inventor
Colin Campion
Mezher Hussein Ali
Michael Glen Orchard
Stephen Martin Courtney
Rajesh Bhikhu Parekh
Original Assignee
Oxford Glycosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939315112A external-priority patent/GB9315112D0/en
Priority claimed from GB939315111A external-priority patent/GB9315111D0/en
Priority claimed from GB939315113A external-priority patent/GB9315113D0/en
Priority claimed from GB939315114A external-priority patent/GB9315114D0/en
Priority claimed from GB939318037A external-priority patent/GB9318037D0/en
Application filed by Oxford Glycosystems Ltd filed Critical Oxford Glycosystems Ltd
Priority to AU71934/94A priority Critical patent/AU7193494A/en
Publication of WO1995003315A2 publication Critical patent/WO1995003315A2/en
Publication of WO1995003315A3 publication Critical patent/WO1995003315A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • This invention relates to mixtures of carbohydrates, their preparation and use.
  • This invention relates also to multi-functional compounds, the use of such compounds to prepare carbohydrate conjugates, the conjugates themselves and also their use, e.g. in therapy and as addressable libraries.
  • Peptide libraries i.e. mixtures of a large number of peptides, are well known and widely used, e.g. for screening for drugs and antibodies.
  • Peptide libraries including solid-phase synthesis methods, and peptide libraries, see Jung et al., Angewandte Chemie 11(4) :367-383 (April 1992), and Birnbaum et al, Current Opinion in Biotech. 3:49 (1992).
  • Glycoamino-acids are known and have been used in the synthesis of glycopeptides.
  • Solution-phase synthesis is described by Kunz. ACIE 26:294 (1987).
  • Solid-phase methods are described by Chadwick et al., Biochem. Soc. Trans. 19:4075 (1991), and by Otvos et al, Tet. Lett. 31:5889 (1990), and Pept. Res. 2:362 (1989).
  • Kahne et al describe mixtures of carbohydrates with a limited number of repeating units, in unequal proportions.
  • Solid-phase oligosaccharide synthesis is potentially rapid and efficient, as has been found for the now widely-used solid-phase syntheses of polypeptides and polynucleotides.
  • coupling efficiency is generally low, and stereospecificity is often lost during glycosidation, as discussed by Malik et al, ChemikerZeitun ⁇ 114 (12):371-375 (1990).
  • Oligosaccharide synthesis in solution is also known, and allows anomeric control.
  • Semi-solid phase synthesis has been proposed, but it is difficult to make the PEG-acceptor sugar conjugate available for coupling at the anomeric position, and cleaving the desired polysaccharide from the PEG often cannot be conducted under convenient conditions.
  • Glycoconjugates comprising carbohydrates linked to polymers, e.g. via ester or thio groups, are known. See Douglas et al, JACS 113:5095-7 (1991).
  • One aspect of the present invention is based on a realisation of the utility of carbohydrate-type libraries.
  • libraries comprise at least 6 different carbohydrates or glycoconjugates, although the number may be much higher, e.g. a minimum of 10, 20, 30, 40, 50, e.g. up to 100, or higher.
  • the library can be used for efficient mass screening of large numbers tif carbohydrates or glycoconjugates, for biological or any other activity.
  • the present invention is based on the realisation that a monosaccharide or other polyhydroxy compound has a variety of different reactive groups which can be used in order to obtain conjugates having a combination of functional moieties in any desired combination of stereochemical or other relationships.
  • a compound of the invention comprises 2, 3, 4, 5 or more independently removable blocking groups.
  • one of the blocking groups may be removed in the same or a separate step.
  • a process for synthesising a polysaccharide of the formula sugar 1 -sugar 2 comprises coupling sugar 2 with a conjugate of the formula Q-sugar 1 , Q being a removable lipophilic or polymeric material, in a solvent for the conjugate; adding a non-solvent for the resultant conjugate Q-sugar 1 -sugar 2 , and removing Q from the resultant coupled conjugate.
  • Q can be chosen so that the conjugate is soluble, but can simply be rendered non- soluble in the system, allowing ease of separation, and also on the discovery of materials Q that are easily separated from the desired conjugate.
  • n represents the number of mono- and/or oligo-saccharide units from which the polysaccharide is derived.
  • Sugar will usually be a monosaccharide; monosaccharides may be used sequentially linked to the sugar-conjugate, but di- and higher saccharides may be coupled in a single step.
  • carbohydrate libraries consisting of di- and trisaccharides, are developed in a fashion formally analogous to the strategy used to develop peptide libraries.
  • Each carbohydrate library consists of multiple compounds, some or all of which may be known. Multiple such libraries may be prepared. Each library can be prepared in such a way as to be fully “addressable", i.e. so as to allow subsequent "decoding” through synthesis of restricted sub-libraries and, if appropriate, chromatographic or other fractionation. This allows the identity of any individual carbohydrate in an active library to be readily addressed.
  • the saccharides can be prepared free of metal ions, solvents and extraneous cytotoxic or other interfering substances, for use in screening assays.
  • many saccharide coupling reactions and conditions are known.
  • Solid-phase syntheses are known (see above); a semi-solid phase synthesis that is the third aspect of this invention is described in more detail below.
  • the different compounds in the library are in equimolar proportions. Depending on the reactants and conditions used, precise equimolarity may not be realistic, although it is desirable to aim for maximum acceptor reactivity.
  • the polyhydroxy compound that is used as a "scaffold" for the purposes of this invention may be any known, say, steroid or sugar molecule, preferably a di-or trihydroxy compound such as a monosaccharide or, for example, cholic acid methyl ester.
  • steroid or sugar molecule preferably a di-or trihydroxy compound such as a monosaccharide or, for example, cholic acid methyl ester.
  • Each such molecule has a number of different active groups, and blocking groups that can be introduced and removed selectively, as desired, e.g. sequentially, and the means for conducting these processes, are well known.
  • first, second and further moieties may be coupled with a compound of the invention in known manner.
  • Various coupling techniques suitable for saccharides, to form glycoconjugates, are known.
  • a compound of the invention may also be used to generate a library of conjugates that is fully addressable, as described above.
  • syntheses are conducted, starting with a trihydroxy compound that may be known per se, to prepare a derivative having combinations of substituents OX, OY and OZ.
  • a compound I may be generated, e.g. with the following substitution profile:
  • the compounds R may be, for example, glycosyl donors, activated lipophiles, phosphorylating agents or a variety of other compounds.
  • the 3 parts are mixed after the reaction has gone to completion, then worked-up and de-O-acetylated to afford a mixture of 18 different compounds.
  • the mixture is then re-divided into 3 parts, one of which is reacted with reagent R 4 , one with R 5 and one with 1 ⁇ .
  • the parts are mixed and worked-up to give a protected library consisting of 54 compounds.
  • the procedure may be extended one more time, making use of the third hydroxy function which is first deprotected (debenzylation).
  • the steps of re-division, separate reactions and re-combination are carried through just as before so that after any required final deprotection steps a library of 162 components is obtained.
  • glycoconjugate libraries consisting of conjugated mono-, di- or tri- saccharides, that may also be developed in a fashion analogous to the strategy used to develop peptide libraries.
  • the characteristics and preparation of such libraries are broadly analogous to those described above for carbohydrate libraries.
  • the acceptor may itself be a glycoconjugate, including one saccharide molecule, to which a second and, if desired, further mono-saccharides are conjugated, by the procedures generally described herein.
  • the acceptor may be a mono-saccharide, di-saccharide or higher holo-saccharide, in which case the donor provides a non-saccharide function.
  • Specific examples of donors are acidic functions such as sulphonate and phosphonate groups, or a mixture of such groups.
  • a sulphonate group may be introduced by reacting the acceptor with excess chlorosulfonic acid.
  • the glycoconjugate may be, for example, a glycopeptide.
  • Glycoamino-acids may be used to prepare glycopeptide libraries, essentially by using them (in suitably protected and activated forms) in place of one or more of the amino-acids used to prepare peptides libraries by known methodology.
  • the term "glycoamino-acid” refers to any natural or unnatural or modified amino-acid coupled to any natural or unnatural or modified sugar (with one or more mono-saccharide residues).
  • sugar moiety and the amino-acid moiety may be linked via an oxygen atom, as in tetra-O-acetyl Glucose- ⁇ -Fmoc-serene, or via a nitrogen atom, as in tri-O-acetyl GlnNa- ⁇ -Fmoc-Asn.
  • oxygen atom as in tetra-O-acetyl Glucose- ⁇ -Fmoc-serene
  • nitrogen atom as in tri-O-acetyl GlnNa- ⁇ -Fmoc-Asn.
  • glycoamino-acids are shown below, as formulae IIA to
  • the coupling gives mixtures that are distinguished from random mixtures by being deliberately controlled and designed, without restriction to means. That means may be, for example, enzymatic or chemical (using excess donor).
  • Monosaccharide Acceptors and Donors Due to the chirality and poly-hydroxy nature of each monosaccharide, several different acceptor and donor forms exist for each monosaccharide for the purpose of chemical conjugation. This property of monosaccharides is uniquely attractive from the point of view of library synthesis, since it allows a relatively large number of individual compounds to be synthesised from relatively few monosaccharides, and with correspondingly low molecular weight.
  • each monosaccharide may be activated at C-1 by means of a thiomethyl activating group and O-benzyl at C-2 (to favour ⁇ -anomeric linkage) or O-acetyl at C-2 to form the ⁇ -anomeric linkage.
  • the protection of the hydroxyl functions at C-3, 4 and 6 may depend on whether a synthetic di-saccharide, linear tri-saccharide, or branched tri-saccharides library is being prepared. In the case of a di-saccharide library, or a library of branched trisaccharide, or the second donor in a library of linear trisaccharide, all hydroxyl functions (other than C-1) may be similarly protected.
  • the donor to form the terminal ß-linked D-galactose linkage in a di-saccharide library, or one of branched tri-saccharides, or the second donor in a library of linear tri-saccharides is of formula III.
  • benzylated thiomethyl derivatives can be easily prepared, as can fully acetylated ones. For the purpose of calculation, it is assumed that twenty donors can be generated from the twelve monosaccharides.
  • the first donor during preparation of a library of linear tri-saccharides to form a glucose linkage may be any of formula IV, wherein one of W, X, Y, and Z is Ac and the other 3 groups are each Bn. Again for the purpose of calculation, it is assumed that forty-two donors of this form can be generated from the twelve example monosaccharides.
  • each monosaccharide may be protected at C-l by benzylation of the C-1 hydroxyl function. Protection of the hydroxyl functions at C-2, 3, 4, and 6 may depend on the form of library that is being prepared, namely di-saccharide, linear tri-saccharide, or branched tri-saccharide. In the case of di-saccharide and linear tri-saccharide libraries, one of the available ring hydroxyl positions may be available and the others protected. For example, the N-acetyl-D-glucosamine acceptors for these two kinds of libraries is formula V, wherein one of X, Y and Z is H, another is Ac and the third is Bn.
  • N-acetyl-D-glucosamine acceptors for this form of library are of formula VI, wherein one of X, Y and Z is H, another is Ac and the third is Bn.
  • Step 1 An equimolar mixture of the 42 acceptor monosaccharides is prepared.
  • Step 2 This mixture is divided into 20 equal aliquots.
  • Step 3 Each aliquot is fully glycosylated with a single donor in large excess.
  • Step 4 Conjugated acceptors are separated from unreacted donor by chromatography.
  • Step 5 The di-saccharide library is fully deprotected.
  • each library consisting of an equimolar consisting of an equimolar amount of each of 42 di-saccharides.
  • Step 1 An equimolar mixture of the 42 acceptor monosaccharides is prepared.
  • Step 2 This mixture of acceptor monosaccharides is divided into N, equal aliquots where N 1 ⁇ 42.
  • Step 3 Each aliquot is fully glycosylated with a single donor, of the form of the first donor for the linear tri-saccharide library. There are 42 such donors.
  • Step 4 Conjugated acceptors are separated from unreacted first donor by chromatography.
  • Step 5 Each di-saccharide library is de-O-acetylated and divided into 20 equal aliquots.
  • Step 6 Each aliquot is fully conjugated with a single donor, of the form of the second donor for the linear tri-saccharide library. There are 20 such donors.
  • Step 7 Conjugated acceptors are separated from unreacted second donor by chromatography.
  • Step 8 The linear tri-saccharide library is fully deprotected.
  • Step 1 An equimolar mixture of the 108 acceptor monosaccharides is prepared.
  • Step 2 This mixture of acceptor monosaccharides is divided into 12 equal aliquots.
  • Step 3 Each aliquot is fully glycosylated with a single donor, of which there are 12 different ones.
  • Step 4 Conjugated acceptors are separated from unreacted first donor by chromatography.
  • Step 5 Each library is de-o-acetylated and divided into
  • Step 6 Each aliquot is fully conjugated with a single donor, of which there are 20 different ones.
  • Step 7 Conjugated acceptors are separated from unreacted second donor by chromatography.
  • Step 8 The branched tri-saccharide library is fully deprotected.
  • the moieties that are introduced may be chosen because of their various biological or physical properties.
  • One or more may have, for example, therapeutic or diagnostic utility, and may be chosen on the basis of such utility.
  • the resulting conjugate according to the invention is suitable for therapeutic use.
  • Reaction Scheme XI ⁇ XII ⁇ XIII ⁇ XIV illustrates a differentially-blocked saccharide of the invention, and its use, to prepare a compound having alkyl, R 11 and R 12 substituents.
  • the specific differentiallyblocked monosaccharide that is shown is (1,4 -di-O-methyl, 3-O-benzyl, 6-O-benzyl, 6-O-tert-butyldimethylsilyl) Galactose.
  • the initial reaction on the differentially-protected monosaccharide is to put on an alkyl chain, perhaps to enhance the oral bio-availability of the final product.
  • the next reaction is to add a grouping R 11 based on AZT.
  • a function R 12 is added which is based for example on the anti-infective agent Flagyl.
  • a structure can be built up which includes two groups having separate therapeutic effects and one group which modifies the bio-availability profile of the structure.
  • the third aspect of this invention is a process that is to give oligosaccharides by sequential coupling reactions.
  • This process is illustrated in the Reaction Scheme XXI (sugar,) + XXII (sugar 2 ) ⁇ XXIII ⁇ XXIV + XXV (sugar 3 ) ⁇ etc, where two differentially-protected molecules (sugar, and sugar 2 ) and a coupling agent are reacted in the first step, the second step involves deprotection, the third coupling etc..
  • a non-solvent is added to cause precipitation, filtration removes deprotecting agent, and solvent is added for redissolution.
  • the coupling is carried out in a solvent such as dichloromethane or acetonitrile; there are many alternatives, in which Q-sugar, is soluble as is sugar 2 .
  • a non-solvent such as ether (again there are alternatives) is added such that, in the resulting solvent mixture, Q-sugar 1 -sugar 2 is insoluble but sugar 2 and coupling agent are still soluble.
  • the required, insoluble coupled material may therefore be filtered off, thus separating it from excess sugar 2 and coupling agent.
  • it is redissolved in solvent, deprotected, reprecipitated and filtered from deprotecting agent.
  • sugar 3 coupling agent added to continue the cycle.
  • the process of the invention is essentially a semi-solid phase synthesis.
  • the support shown in the reaction scheme is modified PEG.
  • the modification involves the use of a benzyl linker group, thereby retaining the desired characteristics of PEG while facilitating removal of the ultimate desired polysaccharide, by hydrogenation.
  • An alternative is DDQ oxidation.
  • the large group is of sufficient size to dramatically alter the physical properties of the conjugate. For example, if the carbohydrate is conjugated to PEG, then the conjugate will be insoluble in ether, and will crystallise from ethanol. Therefore, if the conjugate is treated with a glycosylation agent, then the unaltered conjugate and the glycosylated conjugate can be separated from excess glycosylation agent and by-products, and the conjugates re-glycosylated.
  • precipitatable moiety is coupled to the 1- (or anomeric) position, and via a cleavable linkage. Cleavage is relatively easily performed, e.g. using hydrogenation conditions such as H 2 /Pd, yet elaboration of other positions of the sugar ring is possible.
  • a 504-component linear trisaccharide library with mannose as the central component was constructed:
  • the library was constructed as 14 sub- libraries, 7 of which had all 48 trisaccharide components prepared from non-amino sugars and 7 had 24 trisaccharide components where the reducing monosaccharide was an amino sugar.
  • the sub-library was analysed by P4 gel filtration size exclusion chromatography and found to contain > 80% of the material as trisaccharide components.

Abstract

A library comprises at least six different sugar-containing molecules selected from (i) carbohydrates each derived from at least two saccharide monomers, and (ii) glycoconjugates. Such a library may comprise disaccharides or linear or branched trisaccharides. It may be prepared from a compound having at least two OH groups which are modified by independently-removable blocking groups. A novel process comprises synthesising a polysaccharide of the formula sugarn, n representing the number of mono- and/or oligo-saccharide units from which the polysaccharide may be derived, comprises the steps of coupling sugar2 with a conjugate of the formula Q-sugar1, Q being a removable lipophilic or polymeric material, in a solvent for the conjugate; adding a non-solvent for the resultant conjugate Q-sugar1-sugar2; repeating the said steps n-2 times, as necessary, selecting the sugar to be coupled independently each time; and removing Q from the resultant coupled conjugate.

Description

SACCHARIDES. THEIR SYNTHESIS AND USE
Field of the Invention
This invention relates to mixtures of carbohydrates, their preparation and use. This invention relates also to multi-functional compounds, the use of such compounds to prepare carbohydrate conjugates, the conjugates themselves and also their use, e.g. in therapy and as addressable libraries.
Background of the Invention
Peptide libraries, i.e. mixtures of a large number of peptides, are well known and widely used, e.g. for screening for drugs and antibodies. For a review of peptide synthesis, including solid-phase synthesis methods, and peptide libraries, see Jung et al., Angewandte Chemie 11(4) :367-383 (April 1992), and Birnbaum et al, Current Opinion in Biotech. 3:49 (1992).
Glycoamino-acids are known and have been used in the synthesis of glycopeptides. Solution-phase synthesis is described by Kunz. ACIE 26:294 (1987). Solid-phase methods are described by Chadwick et al., Biochem. Soc. Trans. 19:4075 (1991), and by Otvos et al, Tet. Lett. 31:5889 (1990), and Pept. Res. 2:362 (1989).
Kahne et al describe mixtures of carbohydrates with a limited number of repeating units, in unequal proportions.
Various solid-phase saccharide syntheses have been proposed. By coupling an acceptor sugar to a stationary phase, and conducting the sequential saccharide coupling reactions, to obtain an immobilised polysaccharide, the various reactants and any by-products can be removed from the system before the desired polysaccharide is removed from the support.
Solid-phase oligosaccharide synthesis is potentially rapid and efficient, as has been found for the now widely-used solid-phase syntheses of polypeptides and polynucleotides. However, coupling efficiency is generally low, and stereospecificity is often lost during glycosidation, as discussed by Malik et al, ChemikerZeitunσ 114 (12):371-375 (1990). Oligosaccharide synthesis in solution is also known, and allows anomeric control. However, it is insufficiently rapid for commercial exploitation. Semi-solid phase synthesis has been proposed, but it is difficult to make the PEG-acceptor sugar conjugate available for coupling at the anomeric position, and cleaving the desired polysaccharide from the PEG often cannot be conducted under convenient conditions.
Glycoconjugates, comprising carbohydrates linked to polymers, e.g. via ester or thio groups, are known. See Douglas et al, JACS 113:5095-7 (1991).
Summary of the Invention
One aspect of the present invention is based on a realisation of the utility of carbohydrate-type libraries. For clear distinction from mixtures of carbohydrates or glycoconjugates that may have been prepared, with or without intent, in the past, such libraries comprise at least 6 different carbohydrates or glycoconjugates, although the number may be much higher, e.g. a minimum of 10, 20, 30, 40, 50, e.g. up to 100, or higher. The library can be used for efficient mass screening of large numbers tif carbohydrates or glycoconjugates, for biological or any other activity.
In another aspect, the present invention is based on the realisation that a monosaccharide or other polyhydroxy compound has a variety of different reactive groups which can be used in order to obtain conjugates having a combination of functional moieties in any desired combination of stereochemical or other relationships. For this purpose, a compound of the invention comprises 2, 3, 4, 5 or more independently removable blocking groups. For selective reaction to form a conjugate, one of the blocking groups may be removed in the same or a separate step.
For the avoidance of doubt, there may one or more of any of the blocking groups. Thus, for example, there may be a first group removable under first conditions, a second group removable under second conditions, and two third groups removable under third conditions. According to a further aspect of the invention, a process for synthesising a polysaccharide of the formula sugar1-sugar2 comprises coupling sugar2 with a conjugate of the formula Q-sugar1, Q being a removable lipophilic or polymeric material, in a solvent for the conjugate; adding a non-solvent for the resultant conjugate Q-sugar1-sugar2, and removing Q from the resultant coupled conjugate. This is based on the discovery that Q can be chosen so that the conjugate is soluble, but can simply be rendered non- soluble in the system, allowing ease of separation, and also on the discovery of materials Q that are easily separated from the desired conjugate.
If desired, in this aspect of the invention, the steps recited above may be repeated n-2 times, as necessary, selecting the sugar to be coupled independently each time, to prepare a polysaccharide of the formula sugarn. n represents the number of mono- and/or oligo-saccharide units from which the polysaccharide is derived. Sugar, will usually be a monosaccharide; monosaccharides may be used sequentially linked to the sugar-conjugate, but di- and higher saccharides may be coupled in a single step. Description of the Invention
In one presently preferred embodiment of the invention, carbohydrate libraries, consisting of di- and trisaccharides, are developed in a fashion formally analogous to the strategy used to develop peptide libraries. Each carbohydrate library consists of multiple compounds, some or all of which may be known. Multiple such libraries may be prepared. Each library can be prepared in such a way as to be fully "addressable", i.e. so as to allow subsequent "decoding" through synthesis of restricted sub-libraries and, if appropriate, chromatographic or other fractionation. This allows the identity of any individual carbohydrate in an active library to be readily addressed.
Using suitable procedures, examples of which are known to the skilled man, the saccharides can be prepared free of metal ions, solvents and extraneous cytotoxic or other interfering substances, for use in screening assays. For example, many saccharide coupling reactions and conditions are known. Solid-phase syntheses are known (see above); a semi-solid phase synthesis that is the third aspect of this invention is described in more detail below.
There are significant advantages in being able to perform carbohydrate library synthesis using solid-phase reaction procedures. The principal advantages are more rapid separation of products and reactants, and the ability to increase significantly the molecular diversity, by allowing additional reactions and extensions. Given for the purpose of illustrating the present invention, the following description is premised on solution-phase synthesis. Solution-phase synthesis of carbohydrates is considered completely practical since, even for a trisaccharide library, only two covalent bonds are being formed.
It is preferred that the different compounds in the library are in equimolar proportions. Depending on the reactants and conditions used, precise equimolarity may not be realistic, although it is desirable to aim for maximum acceptor reactivity.
In preparing the library, it is certainly generally preferred that equimolar amounts of differentially-protected acceptors be used. This mixture is then reacted with differentially-protected donors. Protected compounds which can be used as acceptors and donors include the second aspect of this invention.
More generally, the polyhydroxy compound that is used as a "scaffold" for the purposes of this invention may be any known, say, steroid or sugar molecule, preferably a di-or trihydroxy compound such as a monosaccharide or, for example, cholic acid methyl ester. Each such molecule has a number of different active groups, and blocking groups that can be introduced and removed selectively, as desired, e.g. sequentially, and the means for conducting these processes, are well known.
If the "scaffold" is a saccharide, first, second and further moieties may be coupled with a compound of the invention in known manner. Various coupling techniques suitable for saccharides, to form glycoconjugates, are known.
A compound of the invention may also be used to generate a library of conjugates that is fully addressable, as described above. By way of illustration, in order to prepare a chiral template-based/mixed species library, syntheses are conducted, starting with a trihydroxy compound that may be known per se, to prepare a derivative having combinations of substituents OX, OY and OZ. For example, the following 6 possible combinations of a compound I may be generated, e.g. with the following substitution profile:
X = H Y = Ac Z = Bn
X = H Y = Bn Z = Ac
Y = H X = Ac Z = Bn etc..
An equimolar mixture of the 6 versions of A is divided into 3 equal parts. One part is then reacted with a new reagent R1, the second part with a reagent R2 and the final part with R3. The compounds R may be, for example, glycosyl donors, activated lipophiles, phosphorylating agents or a variety of other compounds.
The 3 parts are mixed after the reaction has gone to completion, then worked-up and de-O-acetylated to afford a mixture of 18 different compounds. The mixture is then re-divided into 3 parts, one of which is reacted with reagent R4, one with R5 and one with 1\. Following completion of the reactions, the parts are mixed and worked-up to give a protected library consisting of 54 compounds.
The procedure may be extended one more time, making use of the third hydroxy function which is first deprotected (debenzylation). The steps of re-division, separate reactions and re-combination are carried through just as before so that after any required final deprotection steps a library of 162 components is obtained.
The same procedure may be adopted starting with a dihydroxy compound. In this case, at least one OH group is blocked. Glycosylation with a particular differentially-protected monosaccharide donor thus gives a library of disaccharides. For libraries of larger molecules, selective deprotection and subdivision, and then further coupling, may be repeated, as desired.
Another presently preferred embodiment of the invention lies in glycoconjugate libraries, consisting of conjugated mono-, di- or tri- saccharides, that may also be developed in a fashion analogous to the strategy used to develop peptide libraries. The characteristics and preparation of such libraries are broadly analogous to those described above for carbohydrate libraries. For example, the acceptor may itself be a glycoconjugate, including one saccharide molecule, to which a second and, if desired, further mono-saccharides are conjugated, by the procedures generally described herein. Alternatively, the acceptor may be a mono-saccharide, di-saccharide or higher holo-saccharide, in which case the donor provides a non-saccharide function. Specific examples of donors are acidic functions such as sulphonate and phosphonate groups, or a mixture of such groups. By way of illustration, a sulphonate group may be introduced by reacting the acceptor with excess chlorosulfonic acid.
The glycoconjugate may be, for example, a glycopeptide. Glycoamino-acids may be used to prepare glycopeptide libraries, essentially by using them (in suitably protected and activated forms) in place of one or more of the amino-acids used to prepare peptides libraries by known methodology. The term "glycoamino-acid" refers to any natural or unnatural or modified amino-acid coupled to any natural or unnatural or modified sugar (with one or more mono-saccharide residues). The sugar moiety and the amino-acid moiety may be linked via an oxygen atom, as in tetra-O-acetyl Glucose-β-Fmoc-serene, or via a nitrogen atom, as in tri-O-acetyl GlnNa-β-Fmoc-Asn. Other examples of glycoamino-acids are shown below, as formulae IIA to
IIF. These compounds are respectively
Tri-O-acetyl xylose-β Fmoc threonine
Tetra-O-acetyl-glucose-β Fmoc hydroxyproline Tetra-O-acetyl-glucose-β Fmoc serine
Tri-O-acetyl GlCNAc-β Fmoc Asn
Tetra-O-acetyl glucose-β Fmoc Asn
Tetra-O-acetyl glucose-α Fmoc Asn
Further by way of illustration, the invention will now be described by way of example only with reference to specific experimental procedures that may be used to obtain libraries of synthetic carbohydrates.
The coupling gives mixtures that are distinguished from random mixtures by being deliberately controlled and designed, without restriction to means. That means may be, for example, enzymatic or chemical (using excess donor).
Available Monosaccharides: The range of pure monosaccharides available commercially or through very simple synthesis in large amounts (multi-gram to kilogram) is quite large. For the purpose of this invention, and to simplify arithmetic, discussion will be confined to the following twelve monosaccharides. It must be remembered that a significantly larger repertoire of monosaccharides could in fact be used, encompassing fluorinated monosaccharides, de-oxy monosaccharides, and all manner of sugar-based structures.
Group I Monosaccharides Group II Monosaccharides (Tetra-hydroxy) (Penta-hydroxy) A = L-Fucose G = D-Glucose B = D-Xylose H = D-Galactose C = L-Rhamnose I = D-Mannose D = D-Arabinose J = D-Allose E = D-GlcNAc K = D-Talose F = D-GalNAc L = L-Idose
Forms of Libraries: Constraining the number of monosaccharides in a library to be≤3, so as to satisfy the requirement for MW ≤500 for each compound in a library, three kinds of carbohydrate library can be envisaged. They are: disaccharide library Donor - Acceptor linear tri-saccharide library : Donor - Donor - Acceptor branched tri-saccharide library : Donor - Acceptor - Donor
Monosaccharide Acceptors and Donors: Due to the chirality and poly-hydroxy nature of each monosaccharide, several different acceptor and donor forms exist for each monosaccharide for the purpose of chemical conjugation. This property of monosaccharides is uniquely attractive from the point of view of library synthesis, since it allows a relatively large number of individual compounds to be synthesised from relatively few monosaccharides, and with correspondingly low molecular weight.
In donor mode, each monosaccharide may be activated at C-1 by means of a thiomethyl activating group and O-benzyl at C-2 (to favour α-anomeric linkage) or O-acetyl at C-2 to form the β-anomeric linkage. The protection of the hydroxyl functions at C-3, 4 and 6 may depend on whether a synthetic di-saccharide, linear tri-saccharide, or branched tri-saccharides library is being prepared. In the case of a di-saccharide library, or a library of branched trisaccharide, or the second donor in a library of linear trisaccharide, all hydroxyl functions (other than C-1) may be similarly protected. In the case of a library of linear tri-saccharides, for the first donor, one hydroxyl group in the ring may would be acetylated and all others benzylated. This allows specific selective deprotection after the first conjugation, so as to allow subsequent conjugation of the second donor. For example, the donor to form the terminal ß-linked D-galactose linkage in a di-saccharide library, or one of branched tri-saccharides, or the second donor in a library of linear tri-saccharides, is of formula III.
For each of the twelve exemplified monosaccharides, benzylated thiomethyl derivatives can be easily prepared, as can fully acetylated ones. For the purpose of calculation, it is assumed that twenty donors can be generated from the twelve monosaccharides.
The first donor during preparation of a library of linear tri-saccharides to form a glucose linkage may be any of formula IV, wherein one of W, X, Y, and Z is Ac and the other 3 groups are each Bn. Again for the purpose of calculation, it is assumed that forty-two donors of this form can be generated from the twelve example monosaccharides.
The repertoire of donors can therefore be summarised as follows:
Form of Library Number of Number of
First Donors Second Donors Di-saccharide 20
Linear tri-saccharide 42 20
Branched tri-saccharide 12 20
In acceptor mode, each monosaccharide may be protected at C-l by benzylation of the C-1 hydroxyl function. Protection of the hydroxyl functions at C-2, 3, 4, and 6 may depend on the form of library that is being prepared, namely di-saccharide, linear tri-saccharide, or branched tri-saccharide. In the case of di-saccharide and linear tri-saccharide libraries, one of the available ring hydroxyl positions may be available and the others protected. For example, the N-acetyl-D-glucosamine acceptors for these two kinds of libraries is formula V, wherein one of X, Y and Z is H, another is Ac and the third is Bn.
In the case of a library of branched tri-saccharides, one hydroxyl function may be left available, one acetylated, and the others benzylated. For example, the corresponding N-acetyl-D-glucosamine acceptors for this form of library are of formula VI, wherein one of X, Y and Z is H, another is Ac and the third is Bn.
The repertoire of acceptors can therefore be summarised as follows: Form of Library Number of Acceptors Di-saccharide 42
Linear tri-saccharide 42
Branched tri-saccharide 108 The repertoire of donors and acceptors for the three forms of libraries using the twelve monosaccharides listed earlier by way of example, can be summarised as follows: Library No. of No. of No. of
Acceptors First Second
Donors Donors
Di-saccharide 42 20
Linear tri-saccharide 42 42 20 Branched tri-saccharide 108 12 20
All the above listed forms of donors and acceptors can be prepared by the skilled man.
Preparation of Di-saccharide Libraries
Step 1: An equimolar mixture of the 42 acceptor monosaccharides is prepared.
Step 2: This mixture is divided into 20 equal aliquots. Step 3: Each aliquot is fully glycosylated with a single donor in large excess.
Step 4: Conjugated acceptors are separated from unreacted donor by chromatography.
Step 5: The di-saccharide library is fully deprotected.
In this way 20 libraries are prepared, with each library consisting of an equimolar consisting of an equimolar amount of each of 42 di-saccharides.
Preparation of Linear Tri-saccharide Libraries
Step 1: An equimolar mixture of the 42 acceptor monosaccharides is prepared.
Step 2: This mixture of acceptor monosaccharides is divided into N, equal aliquots where N1 ≤ 42.
Step 3: Each aliquot is fully glycosylated with a single donor, of the form of the first donor for the linear tri-saccharide library. There are 42 such donors.
Step 4: Conjugated acceptors are separated from unreacted first donor by chromatography.
Step 5: Each di-saccharide library is de-O-acetylated and divided into 20 equal aliquots.
Step 6: Each aliquot is fully conjugated with a single donor, of the form of the second donor for the linear tri-saccharide library. There are 20 such donors.
Step 7: Conjugated acceptors are separated from unreacted second donor by chromatography.
Step 8: The linear tri-saccharide library is fully deprotected.
Using this approach, two extreme cases can be envisaged. In one case, there are 20 libraries, each containing an equimolar mixture of 42 × 42 = 1764 linear tri-saccharides is prepared. In the other case, 840 libraries are prepared, each containing an equimolar mixture of 42 linear tri-saccharides. Any combination of number of libraries and number of compounds per library could be prepared, in a fully addressable way, by varying N1.
Preparation of Branched Tri-saccharide Libraries
Step 1: An equimolar mixture of the 108 acceptor monosaccharides is prepared.
Step 2: This mixture of acceptor monosaccharides is divided into 12 equal aliquots.
Step 3: Each aliquot is fully glycosylated with a single donor, of which there are 12 different ones.
This generates 12 libraries of 108 compounds in each.
Step 4: Conjugated acceptors are separated from unreacted first donor by chromatography.
Step 5: Each library is de-o-acetylated and divided into
20 equal aliquots.
Step 6: Each aliquot is fully conjugated with a single donor, of which there are 20 different ones.
Step 7: Conjugated acceptors are separated from unreacted second donor by chromatography.
Step 8: The branched tri-saccharide library is fully deprotected.
In this way 240 libraries, each containing an equimolar mixture of 108 branched tri-saccharides, is prepared.
The repertoire of libraries and different carbohydrates per library can be summarised as follows: Form of No. No.
Library Libraries Carbohydrates
per Library
Di-mers 20 42
Linear
tri-mers 20 1764
Branched
tri-mers 240 108
In addition to the basic libraries, further diversity may be incorporated, while still retaining equimolarity of individual carbohydrates. This may be achieved, for example, by
(1) increasing the repertoire of starting monosaccharide;
(2) using modified monosaccharide as starting sources e.g. fluorinated derivatives;
(3) tapping off intermediate di-saccharide mixtures formed during synthesis of tri-saccharide libraries, and using other chemical entities (such as sulphate, phosphate, or various organic groups) as the second donors.
In using the second aspect of this invention, the moieties that are introduced may be chosen because of their various biological or physical properties. One or more may have, for example, therapeutic or diagnostic utility, and may be chosen on the basis of such utility. In this case, the resulting conjugate according to the invention is suitable for therapeutic use.
The following Reaction Scheme XI → XII → XIII → XIV illustrates a differentially-blocked saccharide of the invention, and its use, to prepare a compound having alkyl, R11 and R12 substituents. The specific differentiallyblocked monosaccharide that is shown is (1,4 -di-O-methyl, 3-O-benzyl, 6-O-benzyl, 6-O-tert-butyldimethylsilyl) Galactose. Three reactions with bromides, i.e. octyl bromide, R11Br and R12Br, follow: each is conducted in the presence of a silver salt activator.
The initial reaction on the differentially-protected monosaccharide is to put on an alkyl chain, perhaps to enhance the oral bio-availability of the final product. Following deprotection of the 3-position, the next reaction is to add a grouping R11 based on AZT.
After deprotection of the 6-position, a function R12 is added which is based for example on the anti-infective agent Flagyl.
In this way, a structure can be built up which includes two groups having separate therapeutic effects and one group which modifies the bio-availability profile of the structure.
The third aspect of this invention is a process that is to give oligosaccharides by sequential coupling reactions. This process is illustrated in the Reaction Scheme XXI (sugar,) + XXII (sugar2) → XXIII → XXIV + XXV (sugar3) → etc, where two differentially-protected molecules (sugar, and sugar2) and a coupling agent are reacted in the first step, the second step involves deprotection, the third coupling etc.. After coupling, a non-solvent is added to cause precipitation, filtration removes deprotecting agent, and solvent is added for redissolution.
For example, the coupling is carried out in a solvent such as dichloromethane or acetonitrile; there are many alternatives, in which Q-sugar, is soluble as is sugar2. After coupling, a non-solvent such as ether (again there are alternatives) is added such that, in the resulting solvent mixture, Q-sugar1-sugar2 is insoluble but sugar2 and coupling agent are still soluble. The required, insoluble coupled material may therefore be filtered off, thus separating it from excess sugar2 and coupling agent. Then it is redissolved in solvent, deprotected, reprecipitated and filtered from deprotecting agent. Finally, it is redissolved in solvent, and sugar3 coupling agent added to continue the cycle.
The process of the invention is essentially a semi-solid phase synthesis. The support shown in the reaction scheme is modified PEG. The modification involves the use of a benzyl linker group, thereby retaining the desired characteristics of PEG while facilitating removal of the ultimate desired polysaccharide, by hydrogenation. An alternative is DDQ oxidation.
The large group is of sufficient size to dramatically alter the physical properties of the conjugate. For example, if the carbohydrate is conjugated to PEG, then the conjugate will be insoluble in ether, and will crystallise from ethanol. Therefore, if the conjugate is treated with a glycosylation agent, then the unaltered conjugate and the glycosylated conjugate can be separated from excess glycosylation agent and by-products, and the conjugates re-glycosylated.
It is one advantage of the invention that, as some glycosylation reactions do not go to completion, separation of the conjugates from the reaction mixture allows them to be re-glycosylated with fresh glycosylation agents. Further, by having the conjugate linked via a benzyl group, a wide variety of reagents is compatible with the system, while allowing de-conjugation to take place under mild conditions.
Another advantage of the invention, especially with respect to the prior art, is that the precipitatable moiety is coupled to the 1- (or anomeric) position, and via a cleavable linkage. Cleavage is relatively easily performed, e.g. using hydrogenation conditions such as H2/Pd, yet elaboration of other positions of the sugar ring is possible.
Example
A 504-component linear trisaccharide library with mannose as the central component was constructed:
α
α
Figure imgf000017_0001
7 × 4 × 18 = 504 components
In practice the library was constructed as 14 sub- libraries, 7 of which had all 48 trisaccharide components prepared from non-amino sugars and 7 had 24 trisaccharide components where the reducing monosaccharide was an amino sugar.
Construction of the Sub-library
Figure imgf000017_0002
For the preparation of all monosaccharide sub-units, known carbohydrate synthetic methodology was applied. For all glycosylation reactions, the known activating system consisting of N-iodosuccinamide with a catalytic amount of trifluoromethanesulfonic acid was used, all other conditions being well known in the literature. Other glycosylation reaction conditions would also be applicable to this method. For a general review see Seminars in Cell Biology Vol 3. [ed. R.B.Parekh. R.Dwek] (1992).
The following 12 monosaccharide acceptor components were prepared:
1,3,4,6-tetrabenzylmannose
1,2,4,6-tetrabenzylmannose
1,2,3,6-tetrabenzylmannose
1,2,3,4-tetrabenzylmannose
1,3,4,6-tetrabenzylgalactose
1,2,4,6-tetrabenzylgalactose
1,2,4,6-tetrabenzylgalactose
1,2,3,4-tetrabenzylgalactose
1,3,4,6-tetrabenzylglucose
1,2,4,6-tetrabenzylglucose
1,2,3,6-tetrabenzylglucose
1,2,3,4-tetrabenzylglucose
An equimolar mixture of all 12 was made and divided into 4 equal aliquots.
The following 4 differentially-protected monosaccharide donor components were prepared:
methyl 2-acetyl-3,4,6-tribenzyl-1-thio-α-mannose Ia methyl 3-acetyl-2,4,6-tribenzyl-1-thio-α-mannose Ib methyl 4-acetyl-2,3,6-tribenzyl-1-thio-α-mannose Ic methyl 6-acetyl-2,3,4-tribenzyl-1-thio-α-mannose Id One aliquot of the acceptor components mixture was glycosylated with an excess of la, a second aliquot with an excess of lb and so on, to produce 4 disaccharide mixtures which were then combined, de-O-acetylated by the action of
0.1M sodium methoxide in methanol at room temperature. Excess monosaccharides derived from the donors la-Id were removed by means of normal phase silica gel chromatography and the resulting mixture was glycosylated with an excess of methyl 2,3,4,6-tetra-O-acetyl-1-thio-α-mannose to afford the crude trisaccharide library mixture. Following de-O-acetylation as carried out previously, excess monosaccharide was again removed by silica gel chromatography. The protected sub-library was fully deprotected by hydrogenation at RT and air pressure using
10% Pd/C catalyst.
The sub-library was analysed by P4 gel filtration size exclusion chromatography and found to contain > 80% of the material as trisaccharide components.
All other sub-libraries were similarly constructed.
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000019_0003
Figure imgf000019_0004
Figure imgf000019_0005
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000022_0002
Figure imgf000023_0001

Claims

1. A library of at least 6 different sugar-containing molecules selected from (i) carbohydrates each derived from at least 2 saccharide monomers, and (ii) glycoconjugates.
2. A library according to claim 1, wherein the number of different sugar-containing molecules is at least 10.
3. A library according to claim 1, wherein the number of different sugar-containing molecules is at least 20.
4. A library according to claim 1, wherein the number of different sugar-containing molecules is at least 30.
5. A library according to any preceding claim, which comprises substantially equimolar amounts of the different sugar-containing molecules.
6. A library according to any preceding claim, wherein the sugar containing molecules are carbohydrates.
7. A library according to claim 6, obtainable by treating a mixture of monosaccharides with a donor monosaccharide under conjugating conditions, and repeating the treatment one or more times, the saccharide in each step being chosen independently.
8. A library according to claim 6 or claim 7, of disaccharides or linear or branched trisaccharides.
9. A library according to any of claims 1 to 5, wherein the sugar-containing molecules are glycoconjugates.
10. A library according to any of claim 9, wherein the glycoconjugates are glycopeptides.
II. A library according to claim 9 or claim 10, obtainable by treating a mixture of saccharides with a conjugating reagent under conjugating conditions.
12. Use of a library according to any preceding claim, for screening.
13. Use according to claim 12, for screening for activity against a defined therapeutic molecule or activity.
14. A compound having at least 2 OH groups which are modified by independently-removable blocking groups.
15. A compound according to claim 14, which has at least 3 OH groups and at least 2 of them are modified by independently-removable blocking groups.
16. A compound according to claim 14 or claim 15, which is cyclic.
17. A compound according to claim 16, which is a blocked monosaccharide.
18. A compound according to any of claims 14 to 17, which is chiral (with or without the blocking groups).
19. Use of a compound according to any of claims 14 to 18, for the manufacture of a conjugate in which said compound is bonded to at least two different components.
20. Use according to claim 19, in which the conjugate comprises 2, 3, 4 or 5 different said components.
21. Use according to claim 19 or claim 20, in which said compound is a saccharide and the said different components are not.
22. A conjugate as defined in any of claims 19 to 21, for use in therapy or diagnosis, in which at least one of the different components has therapeutic or diagnostic utility.
23. Use of a conjugate of claim 22, for the manufacture of a medicament for use in therapy associated with the or each utility.
24. A library of conjugates as defined in any of claims 19 to 21.
25. A library according to claim 24, which comprises substantially equimolar amounts of the conjugates.
26. A process for preparing a library according to claim 24 or claim 25, which comprises the steps of:
reacting a plurality of samples of a mixture of compounds according to any of claims 14 to 18 with a respective plurality of reagents that replace a blocking group or react with a free OH group;
removing another blocking group; and
repeating the preceding steps, starting with the products of the previous step, one or more times, as desired.
27. A process for synthesising a polysaccharide of the formula sugarn, n representing the number of mono- and/or oligo-saccharide units from which the polysaccharide may be derived, which comprises the steps of coupling sugar2 with a conjugate of the formula Q-sugar1, Q being a removable lipophilic or polymeric material, in a solvent for the conjugate; adding a non-solvent for the resultant conjugate Q-sugar1-sugar2; repeating the said steps n-2 times, as necessary, selecting the sugar to be coupled independently each time; and removing Q from the resultant coupled conjugate.
28. A process according to claim 27, wherein sugar, is conjugated to Q at the anomeric position.
29. A process according to claim 27 or claim 28, wherein Q is modified PEG.
30. A process according to any of claims 27 to 29, wherein sugar, is coupled via a benzyl group.
31. A process according to any of claims 29 to 30, wherein ether is the non-solvent.
32. A process according to any of claims 27 to 31, wherein any excess sugar2, sugar3 etc. and any activator is removed before each repetition of the said steps.
33. A process according to claim 32, wherein one or more of sugar2, sugar3 etc. is soluble in the solvent.
PCT/GB1994/001575 1993-07-21 1994-07-21 Saccharides, their synthesis and use WO1995003315A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71934/94A AU7193494A (en) 1993-07-21 1994-07-21 Saccharides, their synthesis and use

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB939315112A GB9315112D0 (en) 1993-07-21 1993-07-21 Saccharides
GB939315111A GB9315111D0 (en) 1993-07-21 1993-07-21 Saccharides
GB9315111.6 1993-07-21
GB9315112.4 1993-07-21
GB939315113A GB9315113D0 (en) 1993-07-21 1993-07-21 Saccharides,glycoconjugates and their use
GB939315114A GB9315114D0 (en) 1993-07-21 1993-07-21 Glycoconjugates
GB9315114.0 1993-07-21
GB9315113.2 1993-07-21
GB939318037A GB9318037D0 (en) 1993-08-31 1993-08-31 Multi-functional compounds and their use
GB9318037.0 1993-08-31

Publications (2)

Publication Number Publication Date
WO1995003315A2 true WO1995003315A2 (en) 1995-02-02
WO1995003315A3 WO1995003315A3 (en) 1995-06-01

Family

ID=27517197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/001575 WO1995003315A2 (en) 1993-07-21 1994-07-21 Saccharides, their synthesis and use

Country Status (2)

Country Link
AU (1) AU7193494A (en)
WO (1) WO1995003315A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021850A1 (en) * 1994-02-09 1995-08-17 Martek Biosciences Corporation Generation and screening of synthetic drug libraries
WO1997035202A1 (en) * 1996-03-21 1997-09-25 Princeton University Carbohydrate-based ligand library, assay and method
WO1997041139A2 (en) * 1996-04-17 1997-11-06 Koester Hubert A combinatorial protecting group strategy for multifunctional molecules
WO1997045436A1 (en) * 1996-05-24 1997-12-04 Basf Aktiengesellschaft Carbohydrate derivatives and their solid-phase synthesis
EP0827406A4 (en) * 1995-03-08 1998-03-11
WO1998016536A1 (en) * 1996-10-16 1998-04-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Saccharide library
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
WO1999007718A2 (en) * 1997-08-08 1999-02-18 Aventis Pharma Deutschland Gmbh Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same
WO2000042067A1 (en) * 1999-01-12 2000-07-20 Princeton University Saccharides linked to compounds that bind cell-surface peptides or proteins
EP1153298A1 (en) * 1999-02-17 2001-11-14 Carbozyme NT Ltd Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
EP1501844A1 (en) * 2002-05-03 2005-02-02 Alchemia Limited Disaccharides for drug discovery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000091A1 (en) * 1990-07-02 1992-01-09 Bioligand, Inc. Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
WO1992009300A1 (en) * 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
WO1993006121A1 (en) * 1991-09-18 1993-04-01 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000091A1 (en) * 1990-07-02 1992-01-09 Bioligand, Inc. Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
WO1992009300A1 (en) * 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
WO1993006121A1 (en) * 1991-09-18 1993-04-01 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOLOGICAL CHEMISTRY., vol.264, no.23, 15 August 1989, BALTIMORE US pages 13834 - 13839 MIZUOCHI T. ET AL 'A Library of Oligosaccharide Probes (Neoglycolipids) from N-Glycosylated Proteins Reveals That Conglutinin Binds to Certain Complex-type as Well as High Mannose-type Oligosaccharide chains' *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol.113, no.13, June 1991, GASTON, PA US pages 5095 - 5097 DOUGLAS S.P. ET AL 'Polymer-supported solution synthesis of oligosaccharides' cited in the application *
SYNLETT, no.7, July 1992, STUTTGART DE pages 555 - 557 KANDIL A.A. ET AL 'Synthesis of fragments of the capsular polysaccharide of Haemophilus Influenza type b on a soluble polymeric support' *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5593853A (en) * 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
WO1995021850A1 (en) * 1994-02-09 1995-08-17 Martek Biosciences Corporation Generation and screening of synthetic drug libraries
EP0827406A4 (en) * 1995-03-08 1998-03-11
EP0827406A1 (en) * 1995-03-08 1998-03-11 The Scripps Research Institute Carbopeptoids and carbonucleotoids
WO1997035202A1 (en) * 1996-03-21 1997-09-25 Princeton University Carbohydrate-based ligand library, assay and method
EP0901629A4 (en) * 1996-03-21 2000-02-02 Univ Princeton Carbohydrate-based ligand library, assay and method
EP0901629A1 (en) * 1996-03-21 1999-03-17 Princeton University Carbohydrate-based ligand library, assay and method
WO1997041139A3 (en) * 1996-04-17 1997-12-04 Hubert Koester A combinatorial protecting group strategy for multifunctional molecules
US6828435B2 (en) 1996-04-17 2004-12-07 Hk Pharmaceuticals, Inc. Combinatorial protecting group strategy for multifunctional molecules
WO1997041139A2 (en) * 1996-04-17 1997-11-06 Koester Hubert A combinatorial protecting group strategy for multifunctional molecules
WO1997045436A1 (en) * 1996-05-24 1997-12-04 Basf Aktiengesellschaft Carbohydrate derivatives and their solid-phase synthesis
US6242583B1 (en) 1996-05-24 2001-06-05 Basf Aktiengesellschaft Carbohydrate derivatives and their solid-phase synthesis
CN1131233C (en) * 1996-05-24 2003-12-17 Basf公司 Carbohydrate derivatives and their solid-phase synthesis
DE19642751A1 (en) * 1996-10-16 1998-04-23 Deutsches Krebsforsch Saccharide library
WO1998016536A1 (en) * 1996-10-16 1998-04-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Saccharide library
WO1999007718A2 (en) * 1997-08-08 1999-02-18 Aventis Pharma Deutschland Gmbh Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same
JP2001512737A (en) * 1997-08-08 2001-08-28 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Substituted tetrahydropyran derivatives, processes for their preparation, their use as medicaments or diagnostics and medicaments containing them
WO1999007718A3 (en) * 1997-08-08 1999-09-10 Hoechst Marion Roussel De Gmbh Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same
WO2000042067A1 (en) * 1999-01-12 2000-07-20 Princeton University Saccharides linked to compounds that bind cell-surface peptides or proteins
EP1153298A1 (en) * 1999-02-17 2001-11-14 Carbozyme NT Ltd Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
EP1153298A4 (en) * 1999-02-17 2002-10-23 Glycominds Ltd Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
EP1785726A1 (en) * 1999-02-17 2007-05-16 Carbozyme NT Ltd Combinatioral complex carbohydrate libraries and methods for the manufacture and uses thereof
EP1501844A1 (en) * 2002-05-03 2005-02-02 Alchemia Limited Disaccharides for drug discovery
EP1501844A4 (en) * 2002-05-03 2010-10-27 Alchemia Ltd Disaccharides for drug discovery

Also Published As

Publication number Publication date
WO1995003315A3 (en) 1995-06-01
AU7193494A (en) 1995-02-20

Similar Documents

Publication Publication Date Title
Seeberger et al. Solid Phase Synthesis of Oligosaccharides and Glycoconjugates by the Glycal Assembly Method: A Five Year Retrospective
Garegg Thioglycosides as glycosyl donors in oligosaccharide synthesis
Dwek Novel sequential solid-phase synthesis of N-linked glycopeptides from natural sources
Randolph et al. Major simplifications in oligosaccharide syntheses arising from a solid-phase based method: an application to the synthesis of the Lewis b antigen
Paulsen Haworth Memorial Lecture. Synthesis of complex oligosaccharide chains of glycoproteins
Paulsen Syntheses, conformations and X‐ray structure analyses of the saccharide chains from the core regions of glycoproteins
Geurtsen et al. Chemoselective glycosylations. 2. Differences in size of anomeric leaving groups can be exploited in chemoselective glycosylations
WO1995003315A2 (en) Saccharides, their synthesis and use
JPH08511234A (en) Solution and solid phase formation of glycosidic bonds
Karelin et al. Synthesis of oligosaccharides related to cell wall polysaccharides of the fungi Candida and Aspergillus
Brocke et al. Synthetic tumor-associated glycopeptide antigens from the tandem repeat sequence of the epithelial mucin MUC4
US5587442A (en) Polyglycomers
Kovac et al. Synthesis of ligands related to the O-specific antigen of type 1 Shigella dysenteriae. 3. Glycosylation of 4, 6-O-substituted derivatives of methyl 2-acetamido-2-deoxy-. alpha.-D-glucopyranoside with glycosyl donors derived from mono-and oligosaccharides.
Codée et al. The synthesis of well-defined heparin and heparan sulfate fragments
Seeberger Solid phase oligosaccharide synthesis
Pal et al. One-pot oligosaccharide synthesis: latent-active method of glycosylations and radical halogenation activation of allyl glycosides
Wong et al. Synthetic glycosylation of peptides using unprotected saccharide β-glycosylamines
Pett et al. A Convergent Strategy for the Synthesis of Type‐1 Elongated Mucin Cores 1–3 and the Corresponding Glycopeptides
Karelin et al. Synthesis of oligosaccharide fragments of mannan from Candida albicans cell wall and their BSA conjugates
Johnson et al. Vinyl glycosides in oligosaccharide synthesis (part 5): A latent-active glycosylation strategy for the preparation of branched trisaccharide libraries
Oscarson et al. Syntheses of deoxy analogues of methyl 3, 6-di-O-α-D-mannopyranosyl-α-D-mannopyranoside for studies of the binding site of concanavalin A
Liang et al. One-pot synthesis of branched oligosaccharides by use of galacto-and mannopyranosyl thioglycoside diols as key glycosylating agents
Komarova et al. Combination of 3-O-Levulinoyl and 6-O-Trifluorobenzoyl Groups Ensures α-Selectivity in Glucosylations: Synthesis of the Oligosaccharides Related to Aspergillus fumigatus α-(1→ 3)-d-Glucan
Yoshida et al. Synthesis of a set of di-and tri-sulfated galabioses
Guberman Development of Synthetic Strategies to Address Bottlenecks in Glycan Synthesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ FI GB GE HU JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AU BB BG BR BY CA CN CZ FI GB GE HU JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA